Matches in DBpedia 2016-04 for { ?s ?p "Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.Blosozumab was developed by Eli Lilly and Company."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- Blosozumab abstract "Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.Blosozumab was developed by Eli Lilly and Company.".
- Q4928422 abstract "Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.Blosozumab was developed by Eli Lilly and Company.".
- Blosozumab comment "Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.Blosozumab was developed by Eli Lilly and Company.".
- Q4928422 comment "Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.Blosozumab was developed by Eli Lilly and Company.".